Contact:
sales@biotechnologyforums.com to feature here
sales@biotechnologyforums.com to feature here
by mtwalsh01 at 03-09-2015, 08:18 PM
0 comments
A study from scientists in the Ministry of Agriculture in Northwest A&F University, Yangling, China has described production of a herd of genetically engineered cattle with improved resistance to low levels of bovine tuberculosis (TB) infection. The study was published last week in the journal Proceedings of the National Academy of Sciences. The study authors commented: "Our results contribute to the control and prevention of bovine tuberculosis and provide a previously unidentified insight into breeding animals for disease resistance."
Bovine TB is a risk in many parts of the world, including the UK, New Zealand and parts of Africa and Asia. It led to culling of over 26,000 cattle in the UK alone in 2013. It is a chronic infectious disease which affects a broad range of mammalian hosts and is considered a particularly serious threat to agriculture in many less-developed countries.
In the current study, the research team used a genetic engineering system called the transcription activator-like effector nickase (TALEN) system. This enabled them to introduce a mouse gene called SP110 to a specific location in the bovine genome in Holstein–Friesian cattle. Polymorphisms in SP110 have been associated with risk of developing TB in mice, humans and cattle. The results indicated that this modification produced tuberculosis-resistant cattle. Results of both in vitro and in vivo experiments suggested that the transgenic cattle were able to control the growth and multiplication of Mycobacterium bovis, kill the bacteria via apoptosis after infection, and efficiently resist low dose infection with M. bovis transmitted from tuberculous cattle in nature. Use of the TALEN system to ‘knock in’ the mouse SP110 gene thus resulted in a heritable genome modification which was facilitative of TB resistance.
Prof Heiner Niemann, of the Institute of Farm Animal Genetics at Friedrich-Loeffler-Institut, Germany, said that the findings of the study were another step towards the creation of disease resistant livestock animals based on advanced genetic tools. However, he cautioned: "Whether this approach protects cows against TB infection when exposed to high doses of the pathogen remains to be determined."
References:
Wu H et al. (2015). TALE nickase-mediated SP110 knockin endows cattle with increased resistance to tuberculosis. PNAS doi: 10.1073/pnas.1421587112
Ruiz-Larranaga O et al. (2010). SP110 as a novel susceptibility gene for Mycobacterium avium subspecies paratuberculosis infection in cattle. Journal of Dairy Science 93(12):5950-8. DOI: 10.3168/jds.2010-3340
Bovine TB is a risk in many parts of the world, including the UK, New Zealand and parts of Africa and Asia. It led to culling of over 26,000 cattle in the UK alone in 2013. It is a chronic infectious disease which affects a broad range of mammalian hosts and is considered a particularly serious threat to agriculture in many less-developed countries.
In the current study, the research team used a genetic engineering system called the transcription activator-like effector nickase (TALEN) system. This enabled them to introduce a mouse gene called SP110 to a specific location in the bovine genome in Holstein–Friesian cattle. Polymorphisms in SP110 have been associated with risk of developing TB in mice, humans and cattle. The results indicated that this modification produced tuberculosis-resistant cattle. Results of both in vitro and in vivo experiments suggested that the transgenic cattle were able to control the growth and multiplication of Mycobacterium bovis, kill the bacteria via apoptosis after infection, and efficiently resist low dose infection with M. bovis transmitted from tuberculous cattle in nature. Use of the TALEN system to ‘knock in’ the mouse SP110 gene thus resulted in a heritable genome modification which was facilitative of TB resistance.
Prof Heiner Niemann, of the Institute of Farm Animal Genetics at Friedrich-Loeffler-Institut, Germany, said that the findings of the study were another step towards the creation of disease resistant livestock animals based on advanced genetic tools. However, he cautioned: "Whether this approach protects cows against TB infection when exposed to high doses of the pathogen remains to be determined."
References:
Wu H et al. (2015). TALE nickase-mediated SP110 knockin endows cattle with increased resistance to tuberculosis. PNAS doi: 10.1073/pnas.1421587112
Ruiz-Larranaga O et al. (2010). SP110 as a novel susceptibility gene for Mycobacterium avium subspecies paratuberculosis infection in cattle. Journal of Dairy Science 93(12):5950-8. DOI: 10.3168/jds.2010-3340
by debram at 03-07-2015, 03:38 AM
0 comments
Human embryonic stem cells for the first time have been cultured at chemically controlled conditions exclusive of the application of animal material, which is a vital aspect for future clinical uses.
With the discovery of the process of culturing the cells on a matrix of a single human protein: it has now become possible to generate huge quantities of human embryonic stem cells in a chemically defined. In the newly formed embryo, the protein laminin-511 is required to keep stem cells as stem cells. Laminin is needed with the once the embryo starts developing. So far, since it is quite not possible to extract and produce laminin from tissues it becomes difficult for the researchers to access various forms of laminin . However over the past couple of decades, a research group headed by Karl Tryggvason's has cloned the genes for most of the laminins in human, investigated their biological role, illustrated two genetic diseases and, at present applying gene technology, generated various retypes of laminin. Using recombinant techniques the researchers produced the laminin-511. The scientists and researchers at the Harvard Stem Cell Institute also reported that in the similar manner it is possible to culture cells known as reprogrammed stem cells, that has been transformed "back" from tissue cells to stem cells.
Scientists and researchers at Sweden’s Karolinska Institutet, produced human stem cells devoid of other cells from animals, in an entirely chemically-defined ambiance. So far embryonic stem cells have been cultured by means of animal proteins, excluding the possibility of applying them for human treatment. At present, they have been cultivated on a matrix of a distinct human protein: laminin-511, a component of our connective tissue, a matrix that helps cell to connect to. This is a highly promising research since it may enable scientists to build up various cell types that can lead to management of various human diseases.
It is possible to transform the embryonic stem cells into other cell type in the body and can be potentially applied for replacement of abnormal cells. However one of the major setbacks is that it is quite hard to avoid contamination while developing and culturing human embryonic stem cells. At present they are cultured with the help of animal proteins, which overrules the possibility of ensuing application in the treatment of humans. On the other hand, it is possible to culture stem cells on other human cells, recognized as feeder cells, however these cells discharge huge amount of uncontrolled proteins thereby resulting in contradictory research results.
With the discovery of the process of culturing the cells on a matrix of a single human protein: it has now become possible to generate huge quantities of human embryonic stem cells in a chemically defined. In the newly formed embryo, the protein laminin-511 is required to keep stem cells as stem cells. Laminin is needed with the once the embryo starts developing. So far, since it is quite not possible to extract and produce laminin from tissues it becomes difficult for the researchers to access various forms of laminin . However over the past couple of decades, a research group headed by Karl Tryggvason's has cloned the genes for most of the laminins in human, investigated their biological role, illustrated two genetic diseases and, at present applying gene technology, generated various retypes of laminin. Using recombinant techniques the researchers produced the laminin-511. The scientists and researchers at the Harvard Stem Cell Institute also reported that in the similar manner it is possible to culture cells known as reprogrammed stem cells, that has been transformed "back" from tissue cells to stem cells.
by debram at 03-07-2015, 03:37 AM
0 comments
Application of personalized healthcare for treatment and prevention of several diseases efficiently is in increasing demand in recent times. One of the most vital tools for personalized medicine is Genome sequencing, since it offers the necessary genetic information for identification and management of particular diseases. A nano-pore based sequencer with the aim of directly reading and decoding human DNA more efficiently, quickly and formidably was developed by Roche, a leader in research-focused healthcare and biotechnology, in collaboration with IBM (Armonk, NY, USA), a leading player in the areas information technology, microelectronics,and computational biology.Their target is to decrease the sequencing cost of an individual’s genome to between $100 and $1000 as compared to $9,500-$19,500 charged by companies such as San Diego’s Illumina, one of the leaders in analysis of array-based solutions for DNA, RNA and protein which is already a radical drop in comparison to its previous $48,000 price mark.
According to Manfred Baier, head of Roche applied science, sequencing is an essential tool for personalized healthcare that offers the basic genetic information essential for diagnosis and treatment of various diseases. This potent technology along with the mutual strengths of Roche and IBM– will construct cost effective whole genome sequencing with faster availability to the marketplace than was earlier thought possible.
With the aim of reducing the cost so drastically, researchers working with Roche and IBM are focusing on sequencing of true single molecule that can decode DNA molecules, since they are stranded all the way through a nanometer sized pore in a silicon chip. This is a significant approach towards cost reduction, scalability, throughput, and speed in comparison to other sequencing technologies available currently or in the process.
According to the agreement, Roche will be funding the development of the technology continuously at IBM and offer additional resources in collaboration with Roche's sequencing contributory, 454 Life Sciences. All of the technology based products will be developed and marketed by Roche.
According to Ajay Royyuru, senior manager of the department of computational biology at IBM, with the integration of biotechnology, computational biology, and nanotechnology, a system is being developed that can efficiently and accurately translate DNA into genetic information which is quite significant medically. To slow down and control the motion of DNA through the nano-pore is a major challenge of all nano-pore based technologies that the companies are trying to overcome. This is highly desirable for an accurate decoding of the DNA sequence."
According to Manfred Baier, head of Roche applied science, sequencing is an essential tool for personalized healthcare that offers the basic genetic information essential for diagnosis and treatment of various diseases. This potent technology along with the mutual strengths of Roche and IBM– will construct cost effective whole genome sequencing with faster availability to the marketplace than was earlier thought possible.
by debram at 03-07-2015, 03:33 AM
0 comments
Detection of a novel method to increase oil in tobacco plant by the researchers at the Biotechnology Foundation Laboratories at Thomas Jefferson University is a major breakthrough towards production of biofuel from these plants. Since tobacco plants are very efficient producer of biofuel, use of such plants can prevent exploitation of other agricultural crop. However a major challenge to the researchers was the presence of the precious oil mostly in tobacco seeds while the tobacco plants can produce about 600 kg of seeds per acre only.
Tobacco seeds comprises of nearly 40 percent oil per dry weight. Nevertheless, genetic engineering of the plants can somehow solve this problem by enabling the leaves to produce more oil. One of the project’s researchers, Dr. Andrianov, reported modification of the tobacco plants so as to increase oil production up to 20-fold. According to Andrianov, a promising and effective ‘energy plant’ platform being provided by tobacco, that also could act as a model for the utilization of other plants with high-biomass content required for production of biofuel. Dr. Andrianov stated that tobacco is quite an attractive plant for biofuel production that goes with the idea of using plants not required for food production. Plants were genetically engineered to make the leaves more effective in oil production. It has been found that leaves of tobacco plant contain 1.7 percent to 4 percent of oil per dry weight.
Genetic engineering resulted in over-expression of one of the two genes: the diacyglycerol acytransferase (DGAT) gene or the LEAFY COTYLEDON 2 (LEC2) gene. Modification of the DGAT gene increased oil production up to 5.8 percent per dry weight in the leaves, which is nearly two-fold of the oil produced normally. Modification of LEC2 gene resulted in6.8 percent of oil production per dry weight. Dr. Andrianov and Dr. Nikolai Borisjuk, Jefferson Biotechnology Foundation Laboratories co-authored the paper. Hilary Koprowski, M.D., director of the Jefferson Biotechnology Foundation Laboratories, also contributed to the research.
Tobacco seeds comprises of nearly 40 percent oil per dry weight. Nevertheless, genetic engineering of the plants can somehow solve this problem by enabling the leaves to produce more oil. One of the project’s researchers, Dr. Andrianov, reported modification of the tobacco plants so as to increase oil production up to 20-fold. According to Andrianov, a promising and effective ‘energy plant’ platform being provided by tobacco, that also could act as a model for the utilization of other plants with high-biomass content required for production of biofuel. Dr. Andrianov stated that tobacco is quite an attractive plant for biofuel production that goes with the idea of using plants not required for food production. Plants were genetically engineered to make the leaves more effective in oil production. It has been found that leaves of tobacco plant contain 1.7 percent to 4 percent of oil per dry weight.
Genetic engineering resulted in over-expression of one of the two genes: the diacyglycerol acytransferase (DGAT) gene or the LEAFY COTYLEDON 2 (LEC2) gene. Modification of the DGAT gene increased oil production up to 5.8 percent per dry weight in the leaves, which is nearly two-fold of the oil produced normally. Modification of LEC2 gene resulted in6.8 percent of oil production per dry weight. Dr. Andrianov and Dr. Nikolai Borisjuk, Jefferson Biotechnology Foundation Laboratories co-authored the paper. Hilary Koprowski, M.D., director of the Jefferson Biotechnology Foundation Laboratories, also contributed to the research.
by debram at 03-07-2015, 03:31 AM
0 comments
An extensive study on a group of tumor-forming immune system cells was carried out by the scientists at UCLA’s Jonsson Cancer Center in order to find and demolish dangerous melanomas. According to Dr. Antoni Ribas, senior author of the investigation, the team focused on developing the immune system through genetic engineering to kill cancer cells and represent the function of the immune system at the same moment.
If following insertion of genetically engineered T cells, a patient's tumor fails to react well, researchers could verify by PET scanning if the cells did successfully reach the tumor site and also even if they did, whether they performed as was anticipated. A proper observation of the immune response also present evidences on methods of improved engineering of the lymphocytes to make them more effective in seeking out and attacking the tumors.
According to the investigation, the full grown melanomas in mice utilize a dormant HIV-like virus that makes T- cell receptor armed lymphocytes the destroyer of cancerous cells. The genetically engineered lymphocytes were marked with a reporter gene inserted into to cells that during PET scanning shine “hot” which help the scientists locate the lymphocytes following their injection into the blood stream, move through the lymph nodes and the lungs, and arrive in on the lumps anywhere they may be situated in the body. Although the group constructed and introduced one million genetically engineered lymphocytes approximately into a mouse however they stated that humans require about one billion tumor-seeking cells to combat cancer. The researchers expect to implement the process on human, within approximately one year.
Usually, the cancerous cells are not recognized as enemies by the immune system. The genetically engineered antigen-specific T cell receptors inserted to look out for a tumor antigen on the melanoma cell surface - effectively uncover the cancerous cells, disclosing them as fatal attackers that must be killed.
Imaging the engineered T cells while they look for and hit the cancer cells, the researchers can closely monitor the progression of the immune system during its fight against malignancies that could then improvise the monitoring process to treat melanoma in patients.
The study showed that within two to three days the cells started fighting against the melanoma following their injection into the bloodstreams of the mice. The mice were imaged for 10 days at regular intervals to ensure that the cancerous cells were indeed killed by the lymphocytes. However, the process of killing the malignant cells might take more number of days in human system.
If following insertion of genetically engineered T cells, a patient's tumor fails to react well, researchers could verify by PET scanning if the cells did successfully reach the tumor site and also even if they did, whether they performed as was anticipated. A proper observation of the immune response also present evidences on methods of improved engineering of the lymphocytes to make them more effective in seeking out and attacking the tumors.
by debram at 03-07-2015, 03:28 AM
0 comments
One of the biggest issue affecting health, agriculture, environment, financial sectors is recent times is the “oil-spill”. Scientists from various parts of the world are engaged in research towards oil spill clean ups. Europe has reported the sequenced genome of an oil-eating bacterium that has the ability to quickly and efficiently metabolized oil and cleans up oil spills.
Such organisms will be essential since A. borkumensis has the ability to metabolize compounds of low molecular weight only, that add up to only 70 % of crude oil. Therefore, finding out organisms that could consume the remaining high-molecular-weight compounds, is quite essential. Research towards sequencing of other oil-eating bacteria is in progress in the United States, Japan, Australia.
In the past, bacteria were experimentally applied to clean up the 11 million gallons of crude oil spilled by the Exxon Valdez ashore off the coast of Alaska. While it did not make much variation back then, it is now that scientists presented the entire blueprint of the oil-starving bacteria: Alcanivorax borkumensis, with the facility to optimize the conditions for these organisms making them capable of soaking up the hundreds of millions of liters of oil that penetrate the water bodies each year.
According to Vitor Martins dos Santos of the Helmholtz Center for Infection Research (formerly the German Research Center for Biotechnology) in Braunschweig, Germany one of the co-leaders of the international project, with the entire blueprint for Alcanivorax borkumensis, scientists expects a better understanding of the specific physiological mechanism that facilitate the organism to survive entirely on hydrocarbons. The 2,755 sequenced gene of the organism has been illustrated in the journal ‘Nature Biotechnology’.
While, some bacteria have the ability to metabolize oil, but until now exploiting these potential for remediation has been hesitated. Although the oil-consuming bacteria quite uncommon in uncontaminated surroundings, they are abundant in presence of oil; in oil spills A. borkumensis makes up to 90 % of the microbial populations. It is important to create the optimized conditions for these bacteria to grow faster in oil contaminated areas and metabolize them efficiently. According to de Lorenzo, it has now become a standard practice to include oil-soluble forms of phosphorous and nitrogen to oil spills. However, actual understanding of the specific nutrients required by the bacteria is still awaited.
Since bacterial method of remediation was not quite successful, oil spill cleanup rely much on the use of physical removal of oil with boom and application of chemical dispersants to split the remains. This method is not much acceptable since physically recovery of oil is quite expensive, and chemicals used along with the remaining oil that might not be quite visible are harmful to the environment .
The genomic information obtained from decoding the genome of the organism A. borkumensis has disclosed the mechanism of molecular transport that facilitated the bacteria to procure nutrient from its environment. The research also help recognize the plethora of genes responsible for the production of the bacterial oxidative enzymes required for oil degradation, that should enable the researchers easier to find other organisms with capabilities alike.
Such organisms will be essential since A. borkumensis has the ability to metabolize compounds of low molecular weight only, that add up to only 70 % of crude oil. Therefore, finding out organisms that could consume the remaining high-molecular-weight compounds, is quite essential. Research towards sequencing of other oil-eating bacteria is in progress in the United States, Japan, Australia.
by mtwalsh01 at 03-07-2015, 12:32 AM
1 comments
A new strategy for improved cancer detection via blood-based diagnosis has been described in a recent study in the journal Proceedings of the National Academy of Sciences (PNAS). The study comes from a team of researchers based in Stanford University and in National Yang-Ming University in Taiwan.
Early cancer detection can lead to dramatically improved effectiveness of treatment strategies. Blood-based diagnosis would be a major advantage in this regard, but despite intensive research efforts over decades, many apparently promising blood biomarkers have failed clinically. Problems such as variability of cancer biomarker expression by non-malignant cells and heterogeneity among tumours have proved to be frustratingly intractable.
In the current study, the research team attempted to overcome these issues by artificially engineering the tumour cells to express a reporter which is not normally expressed in any tissue. The researchers used nonviral safe vectors called “tumor-activatable minicircles”. These used the pan-tumour–specific survivin promoter to drive expression of a secretable reporter. The minicircles were systemically administered to mice that were expressing human melanoma metastases and also to tumour-free mice. The results indicated that by measuring blood reporter levels, tumour-bearing mice could be reliably distinguished from tumour-free mice for up to two weeks. Furthermore, tumour burden in the lungs correlated with cumulative reporter levels, indicating that the extent of disease progression could also be determined.
The study authors suggested that their test could first be used in patients with a high risk for tumour recurrence, then for diagnostic screening of high-risk populations and, if proven safe and effective, for the general population. They concluded: “Our system represents an alternative paradigm for improved cancer detection and could enable more timely interventions to combat this devastating disease.”
Reference: Ronald JA, Chuang H-Y, Dragulescu-Andrasi A, Hori SS, Gambhir SS. Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker. PNAS (2015) doi: 10.1073/pnas.1414156112
Early cancer detection can lead to dramatically improved effectiveness of treatment strategies. Blood-based diagnosis would be a major advantage in this regard, but despite intensive research efforts over decades, many apparently promising blood biomarkers have failed clinically. Problems such as variability of cancer biomarker expression by non-malignant cells and heterogeneity among tumours have proved to be frustratingly intractable.
In the current study, the research team attempted to overcome these issues by artificially engineering the tumour cells to express a reporter which is not normally expressed in any tissue. The researchers used nonviral safe vectors called “tumor-activatable minicircles”. These used the pan-tumour–specific survivin promoter to drive expression of a secretable reporter. The minicircles were systemically administered to mice that were expressing human melanoma metastases and also to tumour-free mice. The results indicated that by measuring blood reporter levels, tumour-bearing mice could be reliably distinguished from tumour-free mice for up to two weeks. Furthermore, tumour burden in the lungs correlated with cumulative reporter levels, indicating that the extent of disease progression could also be determined.
The study authors suggested that their test could first be used in patients with a high risk for tumour recurrence, then for diagnostic screening of high-risk populations and, if proven safe and effective, for the general population. They concluded: “Our system represents an alternative paradigm for improved cancer detection and could enable more timely interventions to combat this devastating disease.”
Reference: Ronald JA, Chuang H-Y, Dragulescu-Andrasi A, Hori SS, Gambhir SS. Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker. PNAS (2015) doi: 10.1073/pnas.1414156112
by pitximask at 03-02-2015, 06:32 PM
0 comments
1. I run protein SDS-page. The beginning, the protein bands were appearance, but then running back, i did not see any band. Who answer me why? I asked my teacher, he said that contents of protein not enough. But after condensed sample that shows no band.
2. I run SDS-page according to the method of Laemmli (1970), I mixed stacking gel 3%, it was polymerized about 15 minutes . But after I also do the same protocol that was not polymerize to 1 hour. Who can explain to me?
Here are recipes stacking gel 3% of Laemmli protocol:
2.5 ml 4X Stacking Gel Buffer
6.5 ml dH2O
1.0 ml acrylamide (29: 1)
200 microliter of 10% APS
20 microliter of TEMED
* 4X Stacking Gel Buffer
0.5 M Tris pH 6.8 6,06g, pH to 6.8 with HCl
0.4% SDS 0.4 g SDS
up to 100 ml with dH2O
3. Protein of salted squid less protein of fresh squid. Is protein of salted squid went outside in salted environment?
Thank you very much!
2. I run SDS-page according to the method of Laemmli (1970), I mixed stacking gel 3%, it was polymerized about 15 minutes . But after I also do the same protocol that was not polymerize to 1 hour. Who can explain to me?
Here are recipes stacking gel 3% of Laemmli protocol:
2.5 ml 4X Stacking Gel Buffer
6.5 ml dH2O
1.0 ml acrylamide (29: 1)
200 microliter of 10% APS
20 microliter of TEMED
* 4X Stacking Gel Buffer
0.5 M Tris pH 6.8 6,06g, pH to 6.8 with HCl
0.4% SDS 0.4 g SDS
up to 100 ml with dH2O
3. Protein of salted squid less protein of fresh squid. Is protein of salted squid went outside in salted environment?
Thank you very much!
by lorrainegenscript at 02-28-2015, 07:09 PM
0 comments
GenScript USA Inc, a leading biology CRO and its affiliates announced today that they have entered into a non-exclusive license agreement with the Broad Institute of MIT and Harvard to strengthen their existing GenCRISPR™ services portfolio with the set of extensive intellectual properties and technologies related to CRISPR/Cas9 genome editing systems from the Broad Institute.
GenScript is a leading provider of CRISPR genome editing products and services. Since June 2013, GenScript began developing GenCRISPR™ genome editing services, including gRNA design and constructs and CRISPR/Cas9-based cell line engineering, producing case studies of validated knock-out and knock-in cell lines, and building a bioinformatics tool to aid in the design of gRNAs. The aim is to bring GenScript clients the best quality service and access to the latest advances in CRISPR/Cas9 related technologies. The Broad Institute’s vast CRISPR/Cas9 IP portfolio will be fully utilized to launch new CRISPR-related products and services to satisfy the research and drug discovery needs of GenScript clients.
Dr. Chuan-Chu Chou, Senior Vice President of GenScript comments “CRISPR/Cas9 has great potential to impact research and medicine. Our goal is to provide researchers with a one stop solution for all their CRISPR needs, from gRNA design to cell line engineering. We are very excited to enter this licensing agreement with the Broad. We share Dr. Feng Zhang and the Broad Institute’s vision to make CRISPR accessible to all researchers in order to help make research easy.”
About the Broad Institute of MIT and Harvard
The Eli and Edythe L. Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community.
Founded by MIT, Harvard, and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to http://broadinstitute.org.
About GenScript
Based in Piscataway, New Jersey, GenScript is a leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since its establishment in 2002, GenScript has grown into a global Contract Research Organization that provides services and products to scientists in 86 countries worldwide. The company has built a best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology. For more information, visit http://www.genscript.com.
by achal1 at 02-18-2015, 09:49 PM
0 comments
Two Master research positions pertaining to degree Master in Environmental Engineering are available in my lab at East China Normal University, Shanghai. Interested candidates should email me with their latest CV at varenyam@gmail.com. Fellowship: USD 600 per month, free international dormitory, waived fee plus additional advantages.
by achal at 02-13-2015, 07:10 PM
2 comments
Dear Sir
My Daughter is studying Bsc Bii-Tech and she is in 4th Sem.Pls guide what she should do post completing her Bsc.How she can brigten her job avenues and what field she should choose.
Regards
Achal
My Daughter is studying Bsc Bii-Tech and she is in 4th Sem.Pls guide what she should do post completing her Bsc.How she can brigten her job avenues and what field she should choose.
Regards
Achal
by athensresearch at 02-12-2015, 01:35 AM
4 comments
Athens Research and Technology is a biotechnology company based in Athens, GA, USA that specializes in the production of purified human proteins. We provide our self-manufactured products including custom protein solutions to major biopharmaceutical companies and research laboratories all over the world. ART produces purified lipoproteins, enzymes, transferrin, antibodies, etc. from a variety of different sources, but mainly working with human plasma. Athens Research is a small local company that operates on a global scale, so utmost customer satisfaction is delivered for every single order. As a primary manufacturer, our prices are lower than any other prices for the same product than any other vendor in the biotech market place.
To find more information and contact info, please visit www.athensresearch.com
To find more information regarding the products and services we provide, please visit www.athensresearch.com/produts/all.
To find more information and contact info, please visit www.athensresearch.com
To find more information regarding the products and services we provide, please visit www.athensresearch.com/produts/all.
by Hemmanur Kavya at 02-10-2015, 02:56 PM
0 comments
Hello everyone,
I'm presently in final semester of my engineering in biotechnology. I'm a little confused about what to do next. Whats good MS-bioinformatics or MS-molecular biology. Or should I go for combined Ms-phd program? I have given my GRE exam and got 286. Kindly help me out.
I'm presently in final semester of my engineering in biotechnology. I'm a little confused about what to do next. Whats good MS-bioinformatics or MS-molecular biology. Or should I go for combined Ms-phd program? I have given my GRE exam and got 286. Kindly help me out.
by phanikumar464 at 02-09-2015, 01:06 AM
0 comments
Sir,
I am going to complete b-tech in ECE (Electronics & Communication Engineering) stream in 2015 with aggregate of 74(approximated)...
I wrote GATE exam and i will get a score of 35 out of 100 marks.......
Will i eligible to get MS seat in NUS/NTU in singapore in electronics engineering...?
what are websites useful to get information about MS course through GATE...?
wHAT ARE THE JOB OPPOTUNITIES GOING TO GET IN SINGAPORE BASED ON ELECTRONICS ENGINNERING?
wHEN/where TO APPLY FOR MS in singapore universites?
Regards
phanikumar paruchuri
I am going to complete b-tech in ECE (Electronics & Communication Engineering) stream in 2015 with aggregate of 74(approximated)...
I wrote GATE exam and i will get a score of 35 out of 100 marks.......
Will i eligible to get MS seat in NUS/NTU in singapore in electronics engineering...?
what are websites useful to get information about MS course through GATE...?
wHAT ARE THE JOB OPPOTUNITIES GOING TO GET IN SINGAPORE BASED ON ELECTRONICS ENGINNERING?
wHEN/where TO APPLY FOR MS in singapore universites?
Regards
phanikumar paruchuri
by rosenrot3 at 02-08-2015, 08:41 PM
0 comments
Hello guys
I am studying molecullar and cellular biotechnology in university,since a couple of months.I feel that I am hardly learning anything useful.I am not from the U.S.A.The education standart of my university regarding my study subject seems to be very,very low.Since I am planning to go abroad for my masters,and I am pretty sure that,as things are going now,I never could qualify,I try to learn mostly at home.The problem is,I just don't know where to start,what I have to know :-( .
I always encounter texts that seem to be too advanced,too offtopic.
So,to my question(sorry that it took so long)
If I plan to study molecullar and cellular biotechnology at home,from what basic books do i have to start?to which books should i advance?I am truly confused.I hope somebody has advice.Thanks!
The last book I read was "kuby immunology".I am sure it would be useful in the future,but I doubt it is a good place to start.
Another book I took a look at (today) was
"Introduction to Molecular Biotechnology- Fundamentals, Methods and Applications, An - Michael Wink"
But this seems too complicated to start with too.However,I may be in the wrong and this may be the "standard".I really don't know,I hope you guys have advice :L
PS:I have started to just learn the whole of "encyclopedia of biotechnology by wiley".i am not sure if its the right idea or not,but well...
I am studying molecullar and cellular biotechnology in university,since a couple of months.I feel that I am hardly learning anything useful.I am not from the U.S.A.The education standart of my university regarding my study subject seems to be very,very low.Since I am planning to go abroad for my masters,and I am pretty sure that,as things are going now,I never could qualify,I try to learn mostly at home.The problem is,I just don't know where to start,what I have to know :-( .
I always encounter texts that seem to be too advanced,too offtopic.
So,to my question(sorry that it took so long)
If I plan to study molecullar and cellular biotechnology at home,from what basic books do i have to start?to which books should i advance?I am truly confused.I hope somebody has advice.Thanks!
The last book I read was "kuby immunology".I am sure it would be useful in the future,but I doubt it is a good place to start.
Another book I took a look at (today) was
"Introduction to Molecular Biotechnology- Fundamentals, Methods and Applications, An - Michael Wink"
But this seems too complicated to start with too.However,I may be in the wrong and this may be the "standard".I really don't know,I hope you guys have advice :L
PS:I have started to just learn the whole of "encyclopedia of biotechnology by wiley".i am not sure if its the right idea or not,but well...
by ahens lavigne at 02-06-2015, 07:29 PM
0 comments
Theme: State-of-the-art Trends in Applied Microbial Industries, Biotech and Pharmaceuticals
Featuring 3 days of Scientific workshop, Technical symposium, Special sessions, Speaker & Poster session, and Industrial Expo
Microbiology Conference Detail: World Congress and Expo on Applied Microbiology 2015 is held with the support of international representatives and editorial members from Journal of Vaccines & Vaccination (IF 1.51), Journal of Microbial & Biochemical Technology (IF 2.16), and The Journal of Advances in Genetic Engineering & Biotechnology. Conference proceedings will be published in the subsequent issue release. 2014 Microbiology Conference
Speaker and poster abstract guidelines: Abstract should be 250 words in length followed by the biography of presenting author of upto 100 words. All submitted abstracts will be thoroughly examined by an expert committee. It is recommended to make your submissions at the earliest to give enough feedback time. Final submissions for speaker and poster categories will be accepted only till April 30, 2015. Please request a sample abstract format at : microbiology@conferenceseries.net
2015 Sessions,
Bacteriology, Virology & Mycology (BVM) - Classification of microbes both clinical and industrial has helped to identify the pathogens from symbionts (Session Chair: Dr Joachim Wink, Helmholtz Centre for Infection Research)
Pharmaceutical Industries - Fine tuned microbes are used to produce higher grade antibiotics, vaccines, vitamins, enzymes, dietary supplements and more
Industrial Microbiology - Through out the century science of fermentation and technology has helped beer breweries and fizzy drink factories earn billion around the world
Food Microbiology - Enzymes and microorganisms are used to produce fine quality consumables and also help to study the food spoilages and poisonings. A fine example of cutting edge billion dollar market
Marine Microbiology - Oceans underneath is filled with lifeforms of various sizes. Understanding and transforming their molecular biology for potential use is done with much greater excitement these days
Environmental Microbiology - With the help of bioremediation and biodegradation waste treatment plants has helped recycle the valuable products and safe disposal of hazardous byproducts
Agricultural Micrbiology - Studying the symbionts and soil nature has helped to produce the nutrient rich bio products. Organic food products has greater health benefits and high profit margins
Biofuels/Petroleum Microbiology- More research on finding alternative energy is going, with some of the efforts showing promising results towards the expansion of this science (Session Chair: Armen H. Trchounian, Plants and Microbes Biotechnology)
Academia / Industrial Participation
Microbiology 2015, Germany will witness around 300 and more attedees from Europe and other countries. Professors, Research fellows and scientific eminences will be presented. We will also have the expertise from Bacteriologists, Virologists, Marine biologists, Mycologist, Parasitologists, Instrumentation engineers, System biologists, Genetic and protein engineers, Food processing experts, Soil and agricultural biologist, Ecologist, Chairman/Vice-chairman of industries and other experts of relevant field.
Exhibition, B2B Partnering & Event Collaboration
Microbiology 2015, Germany has exhibitor spaces available for product promotion by industrial exhibitors or act as the potential sponsor to introduce products of academia, industrial and field applications. Exhibitor booths are served on First come First serve basis depending on the space availability. Timely notification to the organizers is highly recommended to make appropriate arrangements. Please call/e-mail to the event organizers for further details.
Featuring 3 days of Scientific workshop, Technical symposium, Special sessions, Speaker & Poster session, and Industrial Expo
Microbiology Conference Detail: World Congress and Expo on Applied Microbiology 2015 is held with the support of international representatives and editorial members from Journal of Vaccines & Vaccination (IF 1.51), Journal of Microbial & Biochemical Technology (IF 2.16), and The Journal of Advances in Genetic Engineering & Biotechnology. Conference proceedings will be published in the subsequent issue release. 2014 Microbiology Conference
Speaker and poster abstract guidelines: Abstract should be 250 words in length followed by the biography of presenting author of upto 100 words. All submitted abstracts will be thoroughly examined by an expert committee. It is recommended to make your submissions at the earliest to give enough feedback time. Final submissions for speaker and poster categories will be accepted only till April 30, 2015. Please request a sample abstract format at : microbiology@conferenceseries.net
2015 Sessions,
Bacteriology, Virology & Mycology (BVM) - Classification of microbes both clinical and industrial has helped to identify the pathogens from symbionts (Session Chair: Dr Joachim Wink, Helmholtz Centre for Infection Research)
Pharmaceutical Industries - Fine tuned microbes are used to produce higher grade antibiotics, vaccines, vitamins, enzymes, dietary supplements and more
Industrial Microbiology - Through out the century science of fermentation and technology has helped beer breweries and fizzy drink factories earn billion around the world
Food Microbiology - Enzymes and microorganisms are used to produce fine quality consumables and also help to study the food spoilages and poisonings. A fine example of cutting edge billion dollar market
Marine Microbiology - Oceans underneath is filled with lifeforms of various sizes. Understanding and transforming their molecular biology for potential use is done with much greater excitement these days
Environmental Microbiology - With the help of bioremediation and biodegradation waste treatment plants has helped recycle the valuable products and safe disposal of hazardous byproducts
Agricultural Micrbiology - Studying the symbionts and soil nature has helped to produce the nutrient rich bio products. Organic food products has greater health benefits and high profit margins
Biofuels/Petroleum Microbiology- More research on finding alternative energy is going, with some of the efforts showing promising results towards the expansion of this science (Session Chair: Armen H. Trchounian, Plants and Microbes Biotechnology)
Academia / Industrial Participation
Microbiology 2015, Germany will witness around 300 and more attedees from Europe and other countries. Professors, Research fellows and scientific eminences will be presented. We will also have the expertise from Bacteriologists, Virologists, Marine biologists, Mycologist, Parasitologists, Instrumentation engineers, System biologists, Genetic and protein engineers, Food processing experts, Soil and agricultural biologist, Ecologist, Chairman/Vice-chairman of industries and other experts of relevant field.
Exhibition, B2B Partnering & Event Collaboration
Microbiology 2015, Germany has exhibitor spaces available for product promotion by industrial exhibitors or act as the potential sponsor to introduce products of academia, industrial and field applications. Exhibitor booths are served on First come First serve basis depending on the space availability. Timely notification to the organizers is highly recommended to make appropriate arrangements. Please call/e-mail to the event organizers for further details.
by yinqiang1984 at 02-06-2015, 12:36 PM
2 comments
Hello, anyone use yeast extract for your fermentation? Which brand you use currently?
by niklas at 02-04-2015, 07:18 PM
0 comments
Hi all,
I'm currently developing a serological dipstick test and I have difficulties in generating robustness in my results. I'm using antibody-HRP as my detection with 4CN as a precipitate but I would like to create a SOP to increase the robustness for my assay. But when i replicate my tests I get quite high variation in the intensities in my spots. Would changing into DAB generate more reproducible results? Is it simply impossible to get a good robustness when using an enzyme reaction to visualise primary antibodies?
all the best
I'm currently developing a serological dipstick test and I have difficulties in generating robustness in my results. I'm using antibody-HRP as my detection with 4CN as a precipitate but I would like to create a SOP to increase the robustness for my assay. But when i replicate my tests I get quite high variation in the intensities in my spots. Would changing into DAB generate more reproducible results? Is it simply impossible to get a good robustness when using an enzyme reaction to visualise primary antibodies?
all the best
by Nuruddin Bahar at 02-02-2015, 06:37 PM
0 comments
I need to write about a new topic or an idea to work on in Biochemistry. Any suggestions ??
by alism01 at 01-31-2015, 07:46 AM
0 comments
I just started masters in medical biotechnology with a background IT. I have some knowledge in UNIX. How can I use this? Or should I learn Linux or some other technology. I want to supplement my interest in biotechnology with some IT platform. Any technology/ program that would benefit my career in MBT. Would really appreciate your insight.